Quality meltdown still affects J&J financials, though Q3 sales are up

Johnson & Johnson ($JNJ) reports today in third-quarter financials that U.S. sales of OTC medicines were "significantly impacted" by the shutdown of McNeil's Consumer Healthcare manufacturing plant in Fort Washington, PA, the main player in its many Tylenol recalls over the last two years. In addition, ongoing remediation work lowered production volumes. Nonetheless, overall sales were up nearly 7% over last year's Q3. Release

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.